JP6615896B2 - アルドステロン合成酵素阻害剤 - Google Patents

アルドステロン合成酵素阻害剤 Download PDF

Info

Publication number
JP6615896B2
JP6615896B2 JP2017539234A JP2017539234A JP6615896B2 JP 6615896 B2 JP6615896 B2 JP 6615896B2 JP 2017539234 A JP2017539234 A JP 2017539234A JP 2017539234 A JP2017539234 A JP 2017539234A JP 6615896 B2 JP6615896 B2 JP 6615896B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
mmol
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017539234A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503647A (ja
JP2018503647A5 (enExample
Inventor
マイケル バレストラ
イェルク ベンツィエン
ジェニファー バーク
デレク コーガン
シン グオ
キース アール ホーンバーガー
ジョン ロード
ケネス エム マイヤーズ
マオリン ユ
ジョンフア ジャン
ジャオミン ション
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2018503647A publication Critical patent/JP2018503647A/ja
Publication of JP2018503647A5 publication Critical patent/JP2018503647A5/ja
Application granted granted Critical
Publication of JP6615896B2 publication Critical patent/JP6615896B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017539234A 2015-01-30 2016-01-28 アルドステロン合成酵素阻害剤 Active JP6615896B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562109890P 2015-01-30 2015-01-30
US62/109,890 2015-01-30
PCT/US2016/015251 WO2016123275A1 (en) 2015-01-30 2016-01-28 Aldosterone synthase inhibitors

Publications (3)

Publication Number Publication Date
JP2018503647A JP2018503647A (ja) 2018-02-08
JP2018503647A5 JP2018503647A5 (enExample) 2019-03-07
JP6615896B2 true JP6615896B2 (ja) 2019-12-04

Family

ID=55361967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017539234A Active JP6615896B2 (ja) 2015-01-30 2016-01-28 アルドステロン合成酵素阻害剤

Country Status (4)

Country Link
US (1) US10131642B1 (enExample)
EP (1) EP3250569B1 (enExample)
JP (1) JP6615896B2 (enExample)
WO (1) WO2016123275A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019149660A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
JOP20200191A1 (ar) 2018-02-02 2020-07-29 Boehringer Ingelheim Int مشتقات أوكسادايازولو بيريدين بها استبدال بسيكليل غير متجانسة للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat)
WO2019149658A1 (en) * 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
EP3746451B1 (en) * 2018-02-02 2023-07-12 Boehringer Ingelheim International GmbH Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
WO2021233884A1 (en) 2020-05-22 2021-11-25 Boehringer Ingelheim International Gmbh Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
EP4153599B1 (en) 2020-05-22 2024-03-13 Boehringer Ingelheim International GmbH Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4544864B2 (ja) * 2002-03-08 2010-09-15 独立行政法人科学技術振興機構 イソキサゾール誘導体及びその製造方法
DE102004035322A1 (de) * 2004-07-21 2006-02-16 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
ES2442347T3 (es) * 2006-03-29 2014-02-11 Novartis Ag Imidazoles como inhibidores de aldosterona sintasa
EP2029604A2 (en) * 2006-05-26 2009-03-04 Novartis AG Aldosterone synthase and/or 11beta-hydroxylase inhibitors
ITMI20062102A1 (it) * 2006-11-02 2008-05-03 Abiogen Pharma Spa Nuovui sali di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidrobenzo-d-isossazol-4-one
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
EP3250569B1 (en) 2019-01-09
JP2018503647A (ja) 2018-02-08
US20180312475A1 (en) 2018-11-01
WO2016123275A1 (en) 2016-08-04
US10131642B1 (en) 2018-11-20
EP3250569A1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
JP6615896B2 (ja) アルドステロン合成酵素阻害剤
RU2518073C2 (ru) Новое бициклическое гетероциклическое соединение
EP2803664B1 (en) Tetrahydrobenzofurane derivatives as gpr40 agonists for the treatment of diabetes
JP6250862B2 (ja) アルドステロン合成酵素阻害薬
TWI843243B (zh) 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途
WO2014036897A1 (zh) 咪唑啉类衍生物、其制备方法及其在医药上的应用
WO2015000412A1 (zh) 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
JP6279812B2 (ja) アルドステロンシンターゼ阻害薬
WO2015032328A1 (zh) 茚满衍生物及其制备方法和在医药上的应用
JP6471153B2 (ja) アルドステロン合成酵素阻害剤としての新規フェニルジヒドロピリジン誘導体
JP2004269468A (ja) ピリミジン誘導体又はその塩
CN101481323B (zh) 苯并环庚烯类衍生物、其制备方法及医药用途
JP6914974B2 (ja) 腎疾患、心血管疾患、および線維性障害の治療に有用な二環式イミダゾール誘導体
JP2010043004A (ja) 新規2環性複素環化合物
JP5667934B2 (ja) 新規2環性複素環化合物からなる医薬
KR20210028649A (ko) Trk 수용체의 조절제로서의 4-치환된 페닐-1,3,5-트리아진 유도체
JP3786983B2 (ja) ピロリジノン誘導体
CN103958484A (zh) 噁唑烷酮类衍生物、其制备方法及其在医药上的应用
CN115785094A (zh) 苄基取代α-咔啉化合物或其药用盐、其药物组合物及其制备方法和用途
CN108239029A (zh) 一类四氢异喹啉化合物及其盐的制备和医药用途
HK1162504B (en) Novel bicyclic heterocyclic compound
HK1220182B (zh) 作为醛固酮合酶抑制剂的苯基-二氢吡啶衍生物
HK1162504A (en) Novel bicyclic heterocyclic compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191106

R150 Certificate of patent or registration of utility model

Ref document number: 6615896

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250